Everolimus News and Research RSS Feed - Everolimus News and Research

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone. [More]
Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. [More]
Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Penn researchers to present clinical data at 2015 ASCO Annual Meeting

Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2. [More]
Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred treatment for the first line of attack. [More]
Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China. [More]
Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development. [More]
Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Patients with multiple narrowed arteries have better outcomes with CABG than with PCI

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Study compares latest drug-coated stents with traditional bypass surgery

Study compares latest drug-coated stents with traditional bypass surgery

Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery. [More]
Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). [More]
Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) were presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 6-9, by Kerin Adelson, M.D., assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven. [More]
Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13. [More]
Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Non-infectious pneumonitis and stomatitis occur more frequently in patients with advanced renal cell carcinoma treated with everolimus than temsirolimus, whereas temsirolimus is associated with a higher incidence of fatigue, rash and asthenia, a retrospective study reports. [More]
Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. [More]
Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. [More]
First-line sunitinib superior to everolimus for metastatic RCC

First-line sunitinib superior to everolimus for metastatic RCC

Results for the RECORD-3 trial support the current strategy of first-line sunitinib followed by second-line everolimus for the treatment of patients with metastatic renal cell carcinoma. [More]
Drug everolimus fails to improve overall survival in advanced liver cancer patients

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Despite strong preclinical data, the drug everolimus failed to improve overall survival in patients with advanced liver cancer, compared to placebo, according to a study in the July 2 issue of JAMA. [More]
Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer. [More]
Docs who treat patients with severe LAM face agonizing treatment decision

Docs who treat patients with severe LAM face agonizing treatment decision

​Doctors who treat patients with a severe and progressive respiratory disease called lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. [More]
Two candidate mTOR therapy biomarkers identified in RCC

Two candidate mTOR therapy biomarkers identified in RCC

Two genes, TSC1 and MTOR, warrant further investigation as biomarkers for treatment benefit with rapalogs in patients with renal cell carcinoma, indicate study results published in Clinical Cancer Research. [More]
Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. [More]
Advertisement
Advertisement